<DOC>
	<DOC>NCT01449357</DOC>
	<brief_summary>A Single-arm Phase II Trial Investigating the Efficacy and Safety of Zalutumumab in Patients with Non-Small Cell Lung Cancer who have Progressive Disease after Treatment with Tyrosine Kinase Inhibitors.</brief_summary>
	<brief_title>Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients must have documented disease progression after TKI treatment (verified by CT scan and/or MRI according to RECIST). Estimated life expectancy of less than 3 months. Received the following treatments within 2 weeks prior to Visit 2: Cytotoxic or cytostatic anticancer chemotherapy Total resection or irradiation of the target lesion Any investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Zalutumumab</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>